Clinical Trials in Philadelphia

Showing 8301-8320 of 20,904 trials

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

NCT04956809

This study will examine whether and how the FDA-approved drug dapagliflozin (Dapa) improves submaximal exercise endurance and skeletal muscle oxidative phosphorylation capacity (SkM OxPhos) in patients with heart failure and reduced left ventricular ejection fraction (HFrEF).

HFrEF

University of Pennsylvania3 participantsStarted Oct 2021

Philadelphia, Pennsylvania, United States

COMPLETEDPhase 1< 1 mile

A Study of PRT2527 in Participants With Advanced Solid Tumors

NCT05159518

This is a Phase 1 dose-escalation and confirmation study of PRT2527, a Cyclin-dependent Kinase 9 (CDK9) inhibitor, in participants with advanced solid tumors. The purpose of this study is to define the dosing schedule, and maximally tolerated dose to be used in subsequent development of PRT2527.

SarcomaCastrate Resistant Prostate CancerHormone Receptor Positive HER2 Negative Breast Cancer+2 more

Prelude Therapeutics30 participantsStarted Feb 2022

Denver, Colorado, United States • Celebration, Florida, United States • Sarasota, Florida, United States +5 more locations

COMPLETEDPhase 27.2 miles

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

NCT01624285

The purpose of this study is to determine if sorafenib (sorafenib tosylate) is a safe and effective treatment option for preventing liver cancer in high risk patients following liver transplantation. Liver transplantation is a treatment option for liver cancer patients, but despite transplantation, the liver cancer can recur in the new, transplanted liver. It is not known whether sorafenib is effective in preventing cancer recurrence in high risk patients following liver transplantation

Adult Primary Hepatocellular CarcinomaLocalized Resectable Adult Primary Liver CancerLocalized Unresectable Adult Primary Liver Cancer+1 more

Jonsson Comprehensive Cancer Center20 participantsStarted Jul 2012

Birmingham, Alabama, United States • Los Angeles, California, United States • Denver, Colorado, United States +18 more locations

Effect of Dapagliflozin on Submaximal Exercise Tolerance in Heart Failure

A Study of PRT2527 in Participants With Advanced Solid Tumors

Sorafenib Tosylate Following a Liver Transplant in Treating Patients With Liver Cancer

Find Trials by Condition in Philadelphia

Effects of Acute Pain on Cognitive Performance in Young Adults

Dexmedetomidine in the Treatment of Agitation Associated With Dementia (TRANQUILITY III)

Double-blind Study to Evaluate the Safety and Efficacy of Antroquinonol in Mild-Moderate COVID-19 Hospitalized Patients

A Study to Evaluate SAGE-217 in Participants With Severe Postpartum Depression

Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant

Study of Narazaciclib (ON 123300) Plus Letrozole in Endometrial Cancer and Other Gynecologic Malignancies

Phase II Trial of Combination Immunotherapy With NeuVax and Trastuzumab in High-risk HER2+ Breast Cancer Patients

Open Label Study of R788 in the Treatment of Persistent/Chronic Immune Thrombocytopenic Purpura (ITP)

JUNIPER: A Phase 2 Study to Evaluate the Safety, Biological Activity, and PK of ND-L02-s0201 in Subjects With IPF

A Study of Efficacy and Safety of Combination Therapy With Guselkumab and Golimumab in Participants With Moderately to Severely Active Ulcerative Colitis

A Clinical Trial to Confirm Safety & Effectiveness of the SYNERGY 4.50 mm and 5.00 mm Stent for Treatment of Atherosclerotic Lesion(s)

iCanCope With Sickle Cell Pain

Maximal Usage Pharmacokinetics and Safety of ARQ-151 in Children With Plaque Psoriasis (ARQ-151-215)

The Canadian/US Integrative Oncology Study

A Study Evaluating the Safety, Tolerability, and Effect on Microvascular Obstruction of Intravenous Temanogrel in Adult Participants Undergoing Percutaneous Coronary Intervention

Association of Endothelial Function and Clinical Outcomes in Subjects Admitted to Chest Pain Unit

Study to Evaluate the Safety and Activity (Including Distribution) of 177Lu-3BP-227 in Subjects With Solid Tumours Expressing Neurotensin Receptor Type 1.